Reactivation of low avidity tumor-specific CD8⁺ T cells associates with immunotherapeutic efficacy of anti-PD-1

Journal article

Data availability statement: Data are available on reasonable request. RNA sequencing data have been deposited in the Gene Expression Omnibus (GEO) under accession number GSE221590. All algorithms used for RNAseq analysis were publicly available R packages. Additional information required is available from the lead contact on request.Background: CD8+ T cells are a highly diverse population of cells with distinct phenotypic functions that can influence immunotherapy outcomes. Further insights on the roles of CD8+ specificities and TCR avidity of naturally arising tumor-specific T cells, where both high and low avidity T cells recognizing the same peptide-major histocompatibility complex (pMHC) coexist in the same tumor, are crucial for understanding T cell exhaustion and resistance to PD-1 immunotherapy. Methods: CT26 models were treated with anti-PD-1 on days 3, 6 and 9 following subcutaneous tumor implantation generating variable responses during early tumor development. Tetramer staining was performed to determine the frequency and avidity of CD8+ T cells targeting the tumor-specific epitope GSW11 and confirmed with tetramer competition assays. Functional characterization of high and low avidity GSW11-specific CD8+ T cells was conducted using flow cytometry and bulk RNA-seq. In vitro cytotoxicity assays and in vivo adoptive transfer experiments were performed to determine the cytotoxicity of high and low avidity populations. Results: Treatment success with anti-PD-1 was associated with the preferential expansion of low avidity (Tetlo) GSW11-specific CD8+ T cells with Vβ TCR expressing clonotypes. High avidity T cells (Tethi), if present, were only found in progressing PD-1 refractory tumors. Tetlo demonstrated precursor exhausted or progenitor T cell phenotypes marked by higher expression of Tcf-1 and T-bet, and lower expression of the exhaustion markers CD39, PD-1 and Eomes compared with Tethi, whereas Tethi cells were terminally exhausted. Transcriptomics analyses showed pathways related to TCR signaling, cytotoxicity and oxidative phosphorylation were significantly enriched in Tetlo found in both regressing and progressing tumors compared with Tethi, whereas genes related to DNA damage, apoptosis and autophagy were downregulated. In vitro studies showed that Tetlo exhibits higher cytotoxicity than Tethi. Adoptive transfer of Tetlo showed more effective tumor control than Tethi, and curative responses were achieved when Tetlo was combined with two doses of anti-PD-1. Conclusions: Targeting subdominant T cell responses with lower avidity against pMHC affinity neoepitopes showed potential for improving PD-1 immunotherapy. Future interventions may consider expanding low avidity populations via vaccination or adoptive transfer.Worldwide Cancer Research Fund (20-0229) awarded to TE and Cancer Research UK Programme Grant (A28279) awarded to TE and EJ

Authors: Sugiyarto, G; Lau, D; Hill, SL; Arcia-Anaya, D; Boulanger, DSM

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: BMJ Publishing Group
• Journal: Journal for ImmunoTherapy of Cancer
• Volume: 11
• Issue: 8
• Pages: e007114-e007114
• Publication date: 2023-08-16
• Acceptance date: 2023-07-31
• DOI: 10.1136/jitc-2023-007114
• EISSN: 2051-1426
• ISSN: 2051-1426
• Language: English
• Keywords: Flow cytometry; Immunotherapy; Interleukin 21; Cytotoxic T cell; Adoptive cell transfer; Population; T cell; In vitro; Antigen; Immunophenotyping; Biochemistry; Molecular biology; Avidity; Immunology; Streptamer; Chemistry; Biology; Cancer research; Immune system; Epitope; Medicine; CD8